2025-06-14-Jefferies-德之馨（SY1）_寻求两全其美的策略-下调至表现不佳（持有）_15页_561kb

Symrise Equity Research Summary - Jefferies (June 15, 2025)

Rating & Target Price: Downgrade to UNDFER, Target Price €90 (from €102.90), -13% YoY change.

Core Recommendations & Views

• Jefferies downgrades Symrise to "Underperform" ("Hold") from its prior rating and reduces its 12-month price target due to concerns over the company's ability to deliver mid-term guidance consistently amidst weakening consumer demand trends, particularly in the US Consumer Staples (P&L shares) segment and Pet Food industry.
• It believes CEO's strategy requires a back-half-weighted year, but H2 2025 volume/market conditions might jeopardize top-line goals, potentially leading to a downgrade in future guidance, impacting its core value proposition of above-market topline growth.

Key Concerns & Risks

1. Consumer Demand & Pet Growth: US Consumer demand concerns persist, hindering volume growth for Symrise's Consumer Ingredients segment. While Private Label market share increase benefits top-line, it may not be truly premium/growth-led. US Pet Food growth appears to have reverted to near-GDP levels or lower post-COVID recovery due to market overbuilding/congestion (competition), potentially pressuring prices, especially seen in SY1's Proteins business. A return to historical above-GDP growth is unlikely until 2028.
2. Margin & Growth Conflict: Symrise aims for "above-cake-and-eat" margin improvement alongside growth, but the analysis questions its capacity for large-scale, impactful cost savings. Suggested areas for savings (portfolio streamlining, sourcing, IT investment-driven optimization) lack transparency or clear aggressiveness. Reinvestments required for growth could offset margin gains. Observed excruciating revenue efficiency per employee compared to peers (Givaudan, IFF, DSM-Firmenich) suggests potential value unlocking from cost/efficiency improvements via better incentives (but risks higher spending) or significant business-level restructuring.

Financial Summary (Selected Future Projections)

• Expected Revenue Organic Growth: ~4%-6% pa mid-term (FY25E: ~3.1%, FY26E: ~4.6%). Lower than pre-COVID historical averages.
• EBITDA Margin Target: 21%-23% by 2028. Current target range implies mid-term performance similar to peers but potentially better cash flow generation. Calculation shows capacity margin might only reach ~20.7% in normalized 2023.
• Reduced JEF Estimates: EBITDA is lowered by ~3% on average for FY25, FY26, FY27 vs. internal forecasts. Revenues slightly increased slightly marginally for FY25E after Jefferies own estimate update.
• DCF Valuation Update: Terminal margin assumptions lowered (13% vs previous 14%), leading to a lower implied DCF multiple (EV/EBITDA 13.4x) compared to SOTP (13.4x) and trading at a 11%EV/EBITDA discount vs key peers (broadening the valuation gap vs strong peers Givaudan, IFF DSMF).

Catalysts

• Performance in H2 FY25 (Catalyst date: July 30). Higher upside case (+26% price) assumes strong organic growth acceleration and peak margins. Downside envisions significantly weaker market share and growth.

Conclusion

Symrise faces challenges balancing the need for continued market share/above-growth-outperformance with delivering significantly better-than-peer margins long-term. Its valuation remains slightly below key peers, but concerns about realizing the potential margin upside and sustained revenue growth make the investment case riskier.